Introduction
Vaccination against human immunodeficiency virus (HIV) infection indeed remains almost the only option as a means to halt the AIDS pandemic [6, 21, 23, 25] . To this effect enormous efforts are being made to develop safe and effective anti-HIV vaccines [10, 16, 20, 24, 29] . In general, live-attenuated vaccines have been shown to be the most effective type of vaccine in controlling pandemics of infectious diseases [10, 29] . In the case of HIV-1, viruses having deletions of genes that have been shown to be associated with disease onset such as nef and vpr [16, 18, 21, 29] are considered to be more suitable for making live attenuated vaccines. However, the possibility of such vaccines reverting to a pathogenic virus [4, 5, 13] due to its high rate of mutation [7] coupling with the non-availability of suitable animal models for evaluating their efficacy and safety [21, 29] raise concerns of their application to humans. To this end, chimeric viruses between simian and human immunodeficiency viruses (SHIVs) that express HIV-1 envelopes on an SIV backbone [16, 20, 24, 29] have been constructed. These SHIVs are infectious to macaques and there are acute pathogenic and non-pathogenic SHIVs that enable the evaluation of the pathogenesis of HIV/SIV in macaque monkeys [6, 21, 23, 29] . They are also being used to develop anti-HIV/SIV attenuated live vaccines or evaluate the efficacy and safety of these vaccines in monkeys [10, 16, 20, 24, 29] .
One outstanding issue is the lack of understanding of immune correlates of protective immunity against HIV infection [6, 7, 13, 21, 23, 26] . Of concern also are those viruses that escape or evade immune pressures and continuously circulate in the host even in the face of mounting humoral and cell-mediated immunity [2, 10, 13, 29] . For this reason some investigators are questioning whether vaccination must just contain HIV replication indefinitely or whether complete eradication of the virus is necessary due to the possibility of the virus reversing to pathogenic state [6, 11, 25, 30] . Thus, evaluating live attenuated anti-HIV vaccines in humans should wait until these concerns have been properly addressed and until there is better understanding of what constitutes adequate and effective immune correlates of vaccination against HIV. In this case, SHIV/macaque model offers the most useful means of addressing these concerns.
We have vaccinated rhesus macaque monkeys with nef-deleted SHIV [17, 19] (SHIV-dn) either intravenously or intranasally, and later challenged them with acute pathogenic SHIV-89.6 P [24] , both intravenously or intravaginally. The vaccinated monkeys were either fully or partially protected as evidenced by stable CD4 + cell counts and by restriction of the replication of the challenge virus [29] and paper in submission]. Viruses isolated from these vaccinated monkeys were all found to be the 89.6 P challenge virus. Therefore, we considered that an in vitro comparative analysis between viruses that were isolated from vaccinated and unvaccinated monkeys will enable us gain some understanding of the mechanism underlying protection by live attenuated vaccines as well the pathogenicity of challenge viruses. Thus, to understand some of the mechanisms used by viruses to overcome the pressures that are intended to limit their replication, we analyzed viruses that were isolated from the vaccinated monkeys.
Results obtained showed that the viruses that were isolated from the vaccinated monkeys were the 89.6 P challenge viruses without any observable recombination. They had very few and different quasi species and replicated poorly in vitro when compared to the parental 89.6 P, implying that the pathogenic properties of these viruses have been impaired.
Materials and methods

Virus isolation from monkeys
Viruses were isolated from monkeys by methods described elsewhere [10, 29] . Briefly 2-4 × 10 6 CD8 + cell-depleted PBMCs were 3-fold serially diluted and added to about 2.5 × 10 6 M8166 cells in 48-well micro-titer plate for 4 weeks in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, and antibiotics. Every 3-4 days for 4 weeks half of the cells were taken and an equivalent amount of medium was added. Medium from the wells that showed signs of cytopathicity was taken and added to fresh M8166 cells in a 10 cm-well dish and observed for syncytial formation. Virus recovery was judged by the observation of the syncytial cytopathic effect and the expression of viral reverse transcriptase activity was detected by RT assay. Viruses that were isolated are summarized in Table 1 .
Differentiation of the isolated viruses
Genomic DNA was extracted from 10 6 virus-infected M8166 cells by a DNeasy TM Tissue Kit (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. Sequences spanning the entire env region were amplified by PCR. PCR was performed as described elsewhere [20, 29] using forward primer (SHenv1F; GACAGGTTAATTGATAGAC) and reverse primer (SHenv7R; GGAGTATTCATATACTGTCCC). PCR products were either digested with Bsu361, DraI, EarI, HincII or HindIII enzymes after which they were separated on 1.5% agarose gels and visualized by ethidium bromide staining. 
Heteroduplex mobility assay (HMA)
HMA was performed on PCR products generated from the whole env and nef regions using primer pairs that amplify between 400 and 600 base pair fragment sizes (in all 7 fragments were generated). Sufficiency of the PCR product was first confirmed on a 1.5% agarose gel. HMA was performed as previously described [12, 28] . Briefly 10 µl of each PCR product was mixed with 2 µl of 10 × annealing buffer {1 M NaCl, 100 mM Tris-HCl (pH 8.0), and 20 mM EDTA (pH 8.0)}, denatured at 95 • C for 5 min and transferred immediately to ice to promote formation of heteroduplexes. Formed heteroduplexes were then separated by electrophoresis through a non-denaturing 5% polyacrylamide gel in Bio-Rad's Mini-PROTEAN R II Electrophoresis Cell (Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules, U.S.A., CA 94547) (100 V for about 1 hr 45 min) and visualized after ethidium bromide staining.
Cells, growth kinetics and reverse transcriptase (RT) activity assay
Replication kinetics of the isolated viruses were examined on human and monkey PBMCs, and M8166 and HSC-F cells by inoculating duplicate cultures of 5 × 10 5 of these cells with 3000 cpm (RT adjusted) of each virus in a 96-well micro-plate as described previously [19, 20] . After inoculation the culture supernatant were collected and assessed for viral replication by judging the RT activity as previously described [17, 19] . Establishment of HSC-F cells have been described previously [1] . Briefly it was established from CD4 + T cells derived from the spleen of the fetus of cynomolgous monkey. The CD4 + T cells, which express some markers of activated or immature T cell phenotype like CD4 and CD8, was immortalized by infection with herpes virus saimiri subtype C. M8166 cells, on the other hand, is a clone derived through limiting dilution of C8166 cells as described elsewhere [9] .
Count of viable cells
The effect of the viruses on cell viability through suppressing of cell division and/or cell killing was examined in monkey PBMC and HSC-F cells. Three thousand cpm (RT adjusted) of each virus was infected to the cells in a 96-well micro-plate as described above. Plates were incubated at 37 • C for 3 days after which 10 µl of WST-8 reagent (Dojindo Laboratories, Kumamoto, Japan) was added to each well and incubated further for 3 hours. The percentage of viable cells in the plate, which corresponds to the intensity of the color of the medium on the cells, was determined with an ELISA plate reader.
CD4 cell down-modulation
The ability of the isolated viruses to down-modulate CD4 cells in vitro was studied in HSC-F cells. Three thousand cpm (RT adjusted) of each virus was infected to 5 × 10 5 HSC-F cells in a 12-well micro-plate. Five hundred microliter of this virus infected-cell was transferred to a new well and an equivalent amount of fresh cells was added every three days. The remaining virus-infected cells were used for FACS analysis as described elsewhere [29] .
Results
Differentiation of the re-isolated viruses
To determine some of the mechanisms involved in the protection by live attenuated vaccines we determined the in vitro biological properties of viruses that were isolated from monkeys that had been vaccinated with gene-deleted vaccines and challenged with acute-pathogenic SHIV-89.6 P. The vaccine virus, SHIV-dn, was derived from SHIV-NM-3rN by deleting the nef gene from SHIV-NM-3rN [17] . SHIV-NM-3rN, which is non-pathogenic, is a chimeric virus from SIVmac239 and HIV-1 NL432 which carries the env, tat, rev, vpr and vpu from the HIV-1 and the other regions from the SIVmac [20] . SHIV-89.6 P, on the other hand, is a highly pathogenic SHIV, which induces acute CD4 lymphopenia and an AIDSlike disease with wasting and opportunistic infections in monkeys. It was obtained through in vivo passage of non-pathogenic SHIV-89.6 which is it self a chimeric virus from SIVmac239 and HIV-1 89.6 [24] . The structure of the env region of the vaccine virus is different from the challenged virus, thus PCR amplification of this region with the primers described in Materials and methods can differentiate between these two viruses by the length and restriction pattern of the PCR product (Fig. 1A) . Using restriction enzymes Bsu361, DraI, EarI, HincII and HindIII to digest the PCR products, as described in Materials and methods, all the viruses isolated from the vaccinated monkeys were found to be the SHIV-89.6 P challenge virus (Fig. 1B-G ).
Heteroduplex mobility assay
The level of viral quasispecies diversity was assessed using HMA. HMA provides an estimate of nucleotide sequence variability based on differential electrophoretic mobility of PCR amplified products [12, 28] . The distribution and number of heteroduplex bands is a measure of virus diversity within the PCR amplified fragment (i.e. a high number of bands on a gel corresponds to a high number of virus variants in the sample [12, 28] ). We first determined the heteroduplex pattern of the entire env and nef regions of the viruses using primer pairs that amplify between 400 and 600 base pair fragment sizes, thus generating 7 fragments as described above. However, we could not find a heteroduplex population in the fragments generated from the start of the env region through the variable regions to about 800 to 1000 nucleotide sequence from the end of the env region. Therefore, we concentrated on the fragments that generated heteroduplex populations (viz. the 3 -end of the env region and 5 -half of the nef region). Two such fragments are the 3 -end of the env region ( Fig. 2A) and 5 -half of the nef region and (Fig. 2B) . It can be seen from the figure that multiple heteroduplex bands with different electrophoretic mobilities were present in all the viruses. Interestingly, almost all the bands that were seen in the parental 89.6 P (lane 1) were also found in viruses from the unvaccinated monkeys (lanes 2 to 4), (the "X" and "Y" marked populations of Fig. 2A and B respectively). In contrast, these populations were not seen in the viruses that were isolated from the vaccinated monkeys (lanes 5 to 9 of both Fig. 2A and B) . Instead, various populations were seen in viruses from the vaccinated monkeys which were also not seen in the parental 89.6 P and viruses from the unvaccinated monkeys ( Fig. 2A and B) . There was not even a consistent HMA banding pattern shared by the viruses isolated from the vaccinated monkeys.
Thus we see that the non-vaccinated monkeys were infected with all the variants that were in the parental 89.6 P while very few populations were selected in the case of vaccinated monkeys. 
Replication kinetics
When the viruses from the vaccinated monkeys were used to infect human and monkey PBMCs and M8166 and HSC-F cells, they showed both delayed kinetics and far lower peaks when compared to the parental 89.6 P and other isolated viruses from unvaccinated-89.6 P-infected monkeys. For example, in human PBMCs the viruses from the vaccinated monkeys started replicating almost two weeks later than the parental and the other viruses. In addition their peak levels were only about 30% of the level of the parental virus and about 50% of the level of the other viruses ( Fig. 3 top left) . Almost the same results were seen in monkey PBMCs except that in the monkey PBMCs the viruses from the vaccinated monkeys started replication almost at the same time as the other viruses but attained peak levels that were only 30% to 50% of those of the other viruses ( Fig. 3 top right) . The poor replication ability of the viruses from the vaccinated monkeys was also seen in established cell lines such as M8166 and HSC-F cells. In these cells the viruses from vaccinated monkeys replicated in the same manner as in the PBMCs. For example in M8166 cells, as in human PBMCs, the viruses from the vaccinated monkeys started replication about 10 days later than the parental 89.6 P and viruses from unvaccinated monkeys, and reached levels that were just 15% to 25% of their levels ( Fig. 3 bottom left) . The viruses from the vaccinated monkeys showed similar low replication ability in HSC-F cells (Fig. 3 bottom right) . Thus the poor replication of viruses from the vaccinated monkeys in vivo was also seen in vitro, suggesting that these viruses have indeed changed in character.
Cytopathicity, and syncytium-induction
Further characterization revealed that, 3 days after infection, the viruses from the vaccinated monkeys could reduce the number of viable cells in monkey PBMCs and HSC-F by only 15% and 20%, respectively, while the parental 89.6 P reduced the number of viable cells in these cells by as much as 60% and 70%, respectively (Fig. 4) . For comparison the viruses from the unvaccinated monkeys reduced the number of viable PBMCs and HSC-F cells 40% and 55%, respectively (Fig. 4) . The reduction in the number of viable cells by the viruses may be due to either cell killing or suppression of cell division, or both. Furthermore, the viruses from the vaccinated monkeys had a delayed effect in down-regulating CD4 surface markers in HSC-F cells. While the parental 89.6 P and the viruses from the unvaccinated monkeys down regulated the CD4 surface markers from as early as 3 days after infection, the viruses from the vaccinated monkeys didn't start to down regulate these markers until after day 5. The degree of down regulation by the viruses from the vaccinated monkeys was also lower. At day 5 it was only about 25% while the degrees of down regulation by parental 89.6 P virus and the viruses from the unvaccinated monkeys were about 78% and 58%, respectively (Fig. 5) . Finally, Taken together, these data demonstrate that the poor replication of the viruses from the vaccinated monkeys in vivo was due to general changes in their biological characteristics.
Discussion
This study was conducted to examine the biological properties of circulating viruses whose replication had been suppressed in vaccinated monkeys as evidenced by stable CD4 + cell counts and restriction of the replication of the challenge virus [29] . This was in an attempt to understand the mechanism underlying protection by live attenuated vaccines as well as the pathogenicity of challenge viruses. We recognized the fact that in vitro conditions are not the same as in vivo conditions and, therefore, in vitro results are not necessarily a reflection of or predictive of what will really happen in vivo. But studies have revealed that at least efficient replication of viruses in cell culture in most cases is predictive of in vivo pathogenicity [3, 14, 22, 27] . The identification of these circulating viruses as the 89.6 P challenge virus indicate that the vaccination did not completely prevent the replication of the challenge virus in the monkeys but rather suppressed its pathogenicity. This confirms previous observation that an immune response, even a powerful one, may not clear the infecting virus from the host [6, 8, 25] .
In vitro phenotype
In vitro, these re-isolated viruses displayed distinct phenotypes when compared to the parental SHIV-89.6 P and other viruses isolated from unvaccinated 89.6 Pinfected monkeys. The viruses isolated from the vaccinated monkeys were reduced in number, replicated poorly in culture, caused minimal reduction of cell viability as well as delayed CD4 cell down-modulation and in-extensive induction of syncytium. This suggests that these circulating viruses in the monkeys have lost their pathogenicity.
Differences in population
One may argue that the differences in replication between the viruses isolated from the vaccinated monkeys and parental SHIV-89.6 P is due to host-specific factors that either favor or hinder target cell susceptibility to viral infection and production. If this is correct, it will imply that the re-isolated viruses are deficient in some unknown properties that are necessary for efficient replication in culture. This implication can be explained by the differences in populations as seen by the HMA. In the HMA, the entire viral population that was present in the parental 89.6 P was also found in the viruses isolated from the unvaccinated monkeys, but they were absent in the viruses isolated from the vaccinated monkeys ( Fig. 2A and B) . Instead, the latter viruses consisted of reduced and different populations. There was not even a consistent HMA banding pattern shared among the viruses isolated from the vaccinated monkeys. Therefore, the populations that were present in the parental 89.6 P and in the unvaccinated monkeys but not in the vaccinated monkeys might be the ones with the pathogenic properties. Another possibility is that the populations found in only the vaccinated monkeys might have been defective in some way in their ability to replicate. Either or both of these mechanisms could explain the differences of replicative characteristics of the viruses.
Cause of changes
Is the reduction of the viral population in the viruses isolated from the vaccinated monkeys due to the vaccination? The most likely answer is yes, because the selection was seen only in the vaccinated monkeys. The major difference between the vaccinated and unvaccinated monkeys is the presence of the vaccine virus in the vaccinated monkeys and therefore one can speculate that the vaccination caused the selection of these non-pathogenic viral variants. As to how the vaccination led to the selection of non-pathogenic viral populations in the vaccinated monkeys, we think either SHIV-89.6 P is composed of both non-pathogenic and pathogenic quasi species, and that the non-pathogenic variants which replicate quite slowly might have escaped recognition and destruction by the immune response induced by the vaccination. Or it is composed of only pathogenic quasi species but during replication, in the presence of the vaccination, which will constitute a bottleneck, mutation might have taken place in some of the populations leading to the loss of pathogenicity. If the former happens to be the case then one can argue that the immune response induced by the vaccination can easily recognize and destroy pathogenic variants that replicate and proliferate faster than the slow-replicating non-pathogenic variants. This would also explain how challenge viruses escape the pressures of vaccination. Another possibility too will be the eradication of pathogenic variants at the infected cellular level, due to the type of viral coded products that would be expressed on the surface of infected cells. Studies are currently on going to determine this possibility.
Conclusion
In conclusion, our in vitro analysis has revealed that though the vaccine virus failed to purge the challenge virus from the monkeys, it has nevertheless effectively contained them by restricting their pathogenicity through selection of non-pathogenic quasispecies. This suggests that if viruses escape immune pressures in the presence of strong and effective HIV vaccination, they might not pose any future danger to the host. Therefore, these results enhances the prospects that these nef-deleted SHIVs can be used as suitable anti-HIV vaccine candidates.
